DNAtrix Virus Expressing T-Cell Co-stimulator OX40L (CD252) Presented at the 2017 Society for Immunotherapy of Cancer Meeting
HOUSTON, Nov. 13, 2017 /PRNewswire/ -- Juan Fueyo, MD, Professor at MD Anderson Cancer Center Department of Neuro-Oncology, presented results of a comprehensive study on the oncolytic virus Delta-24-RGDOX at the 2017 Society for Immunotherapy of Cancer (SITC) Meeting, held in National Harbor, MD on November 10th - 12th.
DNAtrix, an oncolytic virus company, is developing Delta-24-RGDOX (also known as DNX-2440), which locally expresses OX40L (CD252) in tumor cells following infection. The Delta-24-RGDOX backbone is based on the highly potent oncolytic adenovirus, DNX-2401, currently in Phase 2 testing with Merck's checkpoint inhibitor, Keytruda. The data presented at SITC builds on Dr. Fueyo's recent publication in Cancer Research, and demonstrates that Delta-24-RGDOX triggers an antitumor immune response, an abscopal effect, and tumor-specific immune memory, leading to prolonged survival in difficult-to-treat models of cancer.
"DNAtrix is developing best-in-class oncolytic viruses that replicate and persist for weeks to aggressively kill tumor cells while triggering an acute immune response. Delta-24-RGDOX is an excellent example of DNAtrix's platform, as it delivers effective combination therapy for cancers while minimizing side effects and cost," said Frank Tufaro, PhD, CEO of DNAtrix. "We have already shown that DNAtrix oncolytic viruses can be combined safely with other chemotherapies and immunotherapies to provide a new modality for treating cancers."
Details of the presentation:
Efficacious Anti?Melanoma Immunity Induced by OX40 Ligand?Expressing Oncolytic Adenovirus Delta?24?RGDOX
Abstract Number: P409
To access the recently published paper on Delta-24-RGDOX, visit the Cancer Research website http://cancerres.aacrjournals.org/content/77/14/3894.long
For more information about ongoing DNAtrix clinical studies, visit the ClinicalTrials.gov website: NCT02798406 (DNX-2401 + KEYTRUDA for recurrent glioblastoma) and NCT03178032 (DNX-2401 monotherapy for newly diagnosed pediatric diffuse intrinsic pontine glioma).
About DNAtrix Armed Virus Platform
View original content:http://www.prnewswire.com/news-releases/dnatrix-virus-expressing-t-cell-co-stimulator-ox40l-cd252-presented-at-the-2017-society-for-immunotherapy-of-cancer-meeting-300554430.html